Search results for: N
#35045562 2022/01/18 To Up
Lessons Learned from Children Enrolled into the Hepatitis B Virus Research Network Multi-Center Prospective Study.
Sarah Jane Schwarzenberg, Simon C Ling, Philip Rosenthal, Karen F Murray, Jeff Teckman, Douglas Mogul, Norberto Rodriguez-Baez, Kathleen Schwarz
2409 related Products with: Lessons Learned from Children Enrolled into the Hepatitis B Virus Research Network Multi-Center Prospective Study.100ug Lyophilized100ug Lyophilized100ug100ug Lyophilized1100ug Lyophilized100ug Lyophilized500 Units1000 1 mg100 ug 192 Tests
No related Items
#35045559 2022/01/18 To Up
Efficacy and safety of high dose cholecalciferol in patients with inflammatory bowel disease receiving infliximab.Vitamin D deficiency is prevalent in patients with inflammatory bowel disease (IBD). The goal of this study was to assess the efficacy and safety of high-dose, interval cholecalciferol administration in patients with IBD receiving infliximab.
Rebecca J Gordon, Reeder Wells, Camille Johansen, Shanshan Liu, Suzanne E Dahlberg, Scott B Snapper, Paul A Rufo
2912 related Products with: Efficacy and safety of high dose cholecalciferol in patients with inflammatory bowel disease receiving infliximab.2 Pieces/Box4 Arrays/Slide96 wells (1 kit)500 tests4 Membranes/Box2 Pieces/Box4 Membranes/Box4 Membranes/Box
Error loading info... Pleas try again later.
#35045518 // To Up
[Effect of Endoscopic Resection on Prognosis in T1b Colorectal Cancer].With the advancement of endoscopic resection(ER)of colorectal cancer, surgical resection after ER has been increasing. This study evaluated the effects of initial ER on short- and long-term outcomes in T1b colorectal cancer. This retrospective cohort study enrolled patients with pathological T1b colorectal cancer who underwent colorectal surgical resection between 2008 and 2018. A total of 239 eligible patients were divided into 2 groups: patients initially treated using surgical resection with lymph node dissection(LND)(surgery alone, n=142)and patients treated using initial ER and additional surgical resection with LND(surgery after ER, n=97). No significant differences were observed in short-term outcomes(ie, operative time, blood loss, or postoperative complications)or the long-term outcomes(ie, recurrence rate, overall survival rate, or recurrence free survival rate)between groups.
Atsushi Naito, Kazuya Iwamoto, Masahisa Ohtsuka, Mitsunobu Imasato, Satoshi Hyuga, Yujiro Nakahara, Manabu Mikamori, Kenta Furukawa, Jeongho Moon, Tadafumi Asaoka, Kentaro Kishi, Tsunekazu Mizushima, Hiroki Akamatsu
#35045513 // To Up
[A Case of Gastric Perforation Due to an Unresectable Advanced Gastric Cancer That Achieved pCR after Conversion Surgery following SOX plus T-mab Therapy].This case pertains to a 72-year-old man who visited the emergency department with a complaint of upper abdominal pain. On examination, we suspected gastric perforation due to gastric cancer and decided to perform emergency surgery. We performed laparoscopic omentoplasty and collected #4d lymph nodes that were enlarged on CT. The pathological diagnosis was lymph node metastasis. Based on CT findings, we determined it was Bulky N. For initial management, we performed 3 preoperative chemotherapy(SOX therapy)courses and staging laparoscopy. On surgery, extensive disseminated nodules on the abdominal wall, stomach wall, and liver surface were found, and ascites cytology revealed positive findings. Therefore, we did not perform primary lesion resection. Although the disseminated nodule did not pathologically show tumor cells, CY1 was found, resulting to a diagnosis of unresectable gastric cancer. Since the tumor was HER2 3+, we initiated SOX/trastuzumab therapy. After 16 courses, staging laparoscopy was performed as the lymph nodes had shrunk significantly. The results showed no tumor cells in ascites and the disseminated nodules, and laparoscopic total gastrectomy was subsequently performed. Pathological findings showed no tumor cells in the primary lesion or lymph nodes; therefore, a diagnosis of pathological complete response was made. Currently, the patient is alive without recurrence for 6 months after surgery.
Taro Hamasaki, Taku Nishimura, Taiki Kijima, Keisuke Ota, Yoshihiro Tokuhisa, Mihoko Setoguchi
2013 related Products with: [A Case of Gastric Perforation Due to an Unresectable Advanced Gastric Cancer That Achieved pCR after Conversion Surgery following SOX plus T-mab Therapy].
#35045505 // To Up
[A Clinical Study of Orofacial Defect Reconstruction Using a Modified Submental Island Flap following Oral Cancer Resection].Pedicled flaps are used in orofacial defect reconstruction in older patients and patients with underlying diseases. The submental island flap(SIF)is one type of cervical pedicled flap; however, the modified submental island flap (MSIF), which includes mylohyoid muscle, is a simpler and safer type. Here, we report a clinical study of orofacial defect reconstruction using the MSIF following oral cancer resection.
Masaaki Karino, Hiroto Tatsumi, Ichiro Kaneko, Rie Osako, Shinji Ishizuka, Erina Toda, Sho Sato, Satoe Okuma, Tatsuo Okui, Takahiro Kanno
2354 related Products with: [A Clinical Study of Orofacial Defect Reconstruction Using a Modified Submental Island Flap following Oral Cancer Resection].
#35045491 // To Up
[A Case of Spindle Cell Tumor in the Gastric Mucosa Treated with Laparoscopic Local Gastrectomy].The patient was a 43-year-old man. An upper gastrointestinal endoscopic examination revealed a gastric submucosal tumor(SMT)-like, elevated 8-mm lesion in the greater curvature of the upper body of the stomach. It was diagnosed as spindle cell tumor on the basis of biopsy findings, and a gastrointestinal stromal tumor(GIST)was suspected. Various immunohistochemical staining techniques were used; however, a definitive diagnosis could not be achieved. There was no evidence of distant metastasis even on thoracoabdominal computed tomography imaging; thus, the patient was referred to our department for definitive diagnosis and surgical treatment. Laparoscopic local gastrectomy with concomitant intraoperative gastroscopy was performed. Pathological examination of the resected specimen showed a type â ¡c-like lesion with a maximum diameter of 6 mm in the mucosal layer along with spindle cell proliferation. Immunostaining was negative for c- kit, DOG1, CD34, S-100, SMA, WT-1, desmin(N), EMA, and keratin(pan)and positive for Î²-catenin, Bcl-2, and vimentin; furthermore, low Ki-67(MIB-1)expression was detected. Therefore, GIST, solitary fibrous tumor, leiomyoma, leiomyosarcoma, desmoid tumor, spindle cell carcinoma, and synovial sarcoma were excluded, and an unclassifiable spindle cell tumor arising from the gastric mucosa was diagnosed. The patient has remained recurrence-free for 1 year and 8 months post-operatively and is currently under careful outpatient follow-up.
Hidemasa Tamai, Sumi Kobayashi, Hirofumi Suzuki, Tomoya Hatakeyama, Kazuki Sakai, Sosuke Komiyama, Shiro Ogino, Toshikazu Akami, Yuji Ueda, Takeshi Mazaki
1731 related Products with: [A Case of Spindle Cell Tumor in the Gastric Mucosa Treated with Laparoscopic Local Gastrectomy].
#35045490 // To Up
[A Case of Recurrent Gastric Cancer with Durable Complete Response after Short-Term Nivolumab Therapy].We report the case of a patient with recurrent gastric cancer that showed a complete response(CR)after short-term nivolumab administration. A 76-year-old woman was diagnosed with unresectable advanced gastric cancer(T4b, N+, M0, cStage â £A). The patient was administered 7 courses of SOX. Since the primary lesion was reduced significantly after the chemotherapy, radical gastrectomy was performed. Although postoperative adjuvant chemotherapy with weekly nab-PTX was performed, cancer recurrence occurred in the abdominal cavity, and another surgery was performed. However, complete resection was difficult to achieve. Postoperatively, chemotherapy was continued; however, CEA levels increased, and thus RAM+PTX was administered as second-line treatment. Stable disease was maintained for a while; however, disease progression occurred eventually. Thus, RAM+PTX was discontinued after 8 courses, and nivolumab was administered as the third-line treatment. However, due to the rapid deterioration of renal function, nivolumab could not be continued after 3 courses. After nivolumab discontinuation, CEA levels normalized and the image showed CR. Approximately 1.5 years have passed since then, with no report of recurrence without any treatment. Although nivolumab has been shown to be useful as a third-line treatment for unresectable advanced/recurrent gastric cancer, there are few reports demonstrating CR and none showing maintenance of CR after short-term nivolumab administration. Moreover, the rationale of continuing nivolumab is unclear once clinical CR is achieved. Our experience shows the feasibility of discontinuation of short-term nivolumab if CR is achieved.
Keigo Yamamichi, Masanori Yamada, Fusao Sumiyama, Nobuyuki Yamamoto, Yuki Hashimoto, Ryosuke Satake, Masahiko Hatta, Tatsuma Sakaguchi, Masaya Kotsuka, Katsuji Tokuhara, Kentaro Inoue, Mitsugu Sekimoto
2089 related Products with: [A Case of Recurrent Gastric Cancer with Durable Complete Response after Short-Term Nivolumab Therapy].
#35045416 2022/01/19 To Up
A Prospectivly Randomized Phase-II Trial of Axitinib versus Everolimus as Second Line Therapy in Metastatic Renal Cell Carcinoma (BERAT Study).Introduction Inhibition of neo-angiogenesis is a cornerstone of medical treatment in metastatic renal cell carcinoma (mRCC). While 1st line therapies were previously dominated by inhibitors of the vascular endothelial growth factor (VEGF) axis, 2nd line options were less clearly defined. We investigated the role of everolimus (EVE) or a tyrosine kinase inhibitor (TKI) in 2nd line treatment of mRCC patients. Methods Key inclusion criteria were: measurable mRCC , ECOG 0-1, IMDC risk: good or intermediate and adequate organ function. Patients who progressed on or were intolerant to bevacizumab + interferon were subject for randomization between TKI and EVE treatment. Cross-over occurred at time of progression during 2nd line treatment. Improvement of 2nd line PFS-rate at 6 mo. from 50% to 65% was the primary endpoint. Secondary endpoints were PFS, total PFS, ORR, OS, safety and patient reported outcomes. Results In 2012-2015 a total of 22 patients were included. The study was stopped for poor accrual. 10 patients (46%) were randomized to receive 2nd line treatment with everolimus (n=5) or Axitinib (n=4)/ Sunitinib (n=1). ECOG 0 was recorded in 20 % (EVE) and 60% (TKI). Severe adverse events (SAE) occurred in approx. 60% in each arm. ORR was 1/5 (20%) for TKI and 0/5 (0%) for Everolimus. PFS rate at 6 mo. was 20 % in each arm. Median PFS was 3.7 mo. (EVE) and 2.2 mo. (TKI) [HR 1.0 (95%-CI: 0.26-3.85)]. The OS was comparable between arms HR 1.12 (95%-CI: 0.27-4.61). Discussion/Conclusion The rapid change of the treatment landscape, the limited use of BEV/IFN in 1st line and the duration of 1st line treatment jeopardized BERAT trial recruitment. The small number of patients is a major limitation of our trial. Our observation indicated the poor prognosis in progressive patients and the limited efficacy of TKI or mTOR inhbitors in 2nd line treatment.
Viktor GrÃ¼nwald, Thomas Hilser, Johannes Meiler, Peter J Goebell, Philipp Ivanyi, Arne Strauss, Arndt Hartmann, Jens Bedke, Lothar Bergmann
2749 related Products with: A Prospectivly Randomized Phase-II Trial of Axitinib versus Everolimus as Second Line Therapy in Metastatic Renal Cell Carcinoma (BERAT Study).24 tests96 assays96 samples100 plates1 kit96 samples
#35045408 2022/01/19 To Up
Personalized 3D-printed anthropomorphic whole-body phantom irradiated by protons, photons, and neutrons.The objective of this study was to confirm the feasibility of three-dimensionally-printed (3D-printed), personalized whole-body anthropomorphic phantoms for radiation dose measurements in a variety of charged and uncharged particle radiation fields. We 3D-printed a personalized whole-body phantom of an adult female with a height of 154.8 cm, mass of 90.7 kg, and body mass index of 37.8 kg/m. The phantom comprised of a hollow plastic shell filled with water and included a watertight access conduit for positioning dosimeters. It is compatible with a wide variety of radiation dosimeters, including ionization chambers that are suitable for uncharged and charged particles. Its mass was 6.8 kg empty and 98 kg when filled with water. Watertightness and mechanical robustness were confirmed after multiple experiments and transportations between institutions. The phantom was irradiated to the cranium with therapeutic beams of 170-MeV protons, 6-MV photons, and fast neutrons. Radiation absorbed dose was measured from the cranium to the pelvis along the longitudinal central axis of the phantom. The dose measurements were made using established dosimetry protocols and well-characterized instruments. For the therapeutic environments considered in this study, stray radiation from intracranial treatment beams was the lowest for proton therapy, intermediate for photon therapy, and highest for neutron therapy. An illustrative example set of measurements at the location of the thyroid for a square field of 5.3 cm per side resulted in 0.09, 0.59, and 1.93 cGy/Gy from proton, photon, and neutron beams, respectively. In this study, we found that 3D-printed personalized phantoms are feasible, inherently reproducible, and well-suited for therapeutic radiation measurements. The measurement methodologies we developed enabled the direct comparison of radiation exposures from neutron, proton, and photon beam irradiations.
Hunter Tillery, Meagan Moore, Kyle Joseph Gallagher, Phillip J Taddei, Eric Leuro, David C Argento, Gregory B Moffitt, Marissa Kranz, Margaret Carey, Steven Heymsfield, Wayne David Newhauser
2237 related Products with: Personalized 3D-printed anthropomorphic whole-body phantom irradiated by protons, photons, and neutrons.96T100ul50 mg96 tests25 mg100ug100ug100ug10 mg200 1000 tests10 mg
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 Fax 0032 16 50 90 45
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50 Fax 01 43 25 01 60
52062 Aachen Deutschland
Tel 0241 40 08 90 86 Fax 0241 55 91 05 36
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
Schweiz Züri +41435006251
Česká republika Praha +420246019719
Ireland Dublin +35316526556
Norge Oslo +4721031366
Finland Helsset +358942419041
Sverige Stockholm +46852503438
Ελλάς Αθήνα +302111768494
Magyarország Budapest +3619980547
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
Tel 058 710 33 44
Fax 058 710 33 48
GENTAUR Nederland BV
5521 DG Eersel Nederland
Tel 0208-080893 Fax 0497-517897
Piazza Giacomo Matteotti, 6, 24122 Bergamo
Tel 02 36 00 65 93 Fax 02 36 00 65 94
53 Iskar Str. 1191 Kokalyane, Sofia